Loading clinical trials...

Continuous Glucose Monitoring in Polycystic Ovarian Syndrome | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Continuous Glucose Monitoring in Polycystic Ovarian Syndrome

NCT07392476•The Cleveland Clinic

Summary

The purpose of this study is to learn more about blood sugar control in polycystic ovarian syndrome. The patient will be asked to wear a continuous glucose monitor (CGM) device that is applied to the arm with a sensor or filament that goes under the skin to measure your sugar levels. The patient will wear this at certain time points throughout the study. There will have a total of 2 blood draws (about 1 tsp. of blood) at screening and the 6-month visit, a measure of the patients body muscle and fat (body composition), and fill out a questionnaire at the end of the first 3 months and 6 months. Study participation in the research will last about 6 months.

Eligibility

Age

18 - 45 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adult 18-45 years old
•2. Diagnosis of PCOS by usual clinical method such as by Rotterdam criteria
•3. BMI \>25 kg/m2

Exclusion Criteria

•1. Currently on medications that can improve glucose levels such as metformin and glucagon-like receptor 1 agonists (GLP1RA)
•2. Previously intake of above-mentioned medications but less than 3 months since last intake of metformin or less than 6 months since last intake of GLP1RA
•3. Currently on insulin
•4. Does not have Stelo-compatible phone
•5. Fasting glucose \>100 mg/dL (because that is the cutoff for prediabetes) (either labs taken within a week after first visit or within 3 months before start of study
•6. HbA1c \> 5.7% (because this is the cutoff for prediabetes) (either labs taken after screening visit or within 3 months before start of study)
•7. History of anorexia or bulimia
•8. Current or previous CGM use
•9. Use of oral contraceptives at time of enrolment
•10. Intent to become pregnant within 6 months (will need to terminate study if gets pregnant as glucose readings will be affected)
+1 more criteria

Locations (1)

Cleveland Clinic

Cleveland, Ohio, United States

Key Dates

Start Date

December 24, 2025

Primary Completion Date

December 31, 2026

Completion Date

August 15, 2027

Last Updated

February 6, 2026

Enrollment

ESTIMATED participants

Conditions

Polycystic Ovarian Syndrome (PCOS)

Interventions

Stelo glucose biosensor by Dexcom

DEVICE

Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome

NCT07399535

Polycystic Ovarian Syndrome (PCOS)Herbal Medicine+2 more

View study

NOT_YET_RECRUITINGNA

Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients

NCT07169292

Polycystic Ovarian Syndrome (PCOS)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Continuous Glucose Monitoring in Polycystic Ovarian Syndrome

Inclusion Criteria

Exclusion Criteria

Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome

Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome